title: Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias.
abstract: Thirty-seven patients with acute myeloid leukemia in relapse or at initial diagnosis but resistant to conventional induction regimen have been treated by single-cycle timed sequential chemotherapy, including continuous infusion of cytarabine over 72 hours on Days 1-3 and 8-10 and short injections of daunorubicin on Days 1-3. There were 21 complete remissions (56%), 11 failures, and five early deaths. For responders, median durations of complete remission and survival were 7 and 12 months, respectively.
authors.forename: D
authors.initials: D
authors.lastname: Fière
authors.forename: L
authors.initials: L
authors.lastname: Campos
authors.forename: H V
authors.initials: HV
authors.lastname: Van
authors.forename: D
authors.initials: D
authors.lastname: Guyotat
authors.forename: E
authors.initials: E
authors.lastname: Archimbaud
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: J J
authors.initials: JJ
authors.lastname: Viala
authors.forename: P A
authors.initials: PA
authors.lastname: Bryon
authors.forename: J J
authors.initials: JJ
authors.lastname: Milan
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D003630:Daunorubicin